Terns Pharmaceuticals pulls in $87m Series C
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on treating non-alcoholic steatohepatitis and other chronic liver diseases, has secured $87 million in Series C financing.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on treating non-alcoholic steatohepatitis and other chronic liver diseases, has secured $87 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination
